(Q36950436)

17 August 2017

1 reference

title

Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer (English)

1 reference

17 August 2017

0 references

Simone Helmig

1

1 reference

17 August 2017

Joachim Schneider

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

555-568

1 reference

A translational view of the molecular pathogenesis of lung cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum oncoproteins and growth factors in asbestosis and silicosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Detection of serum p53 protein in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Clinical implications of the p53 tumor-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The dual role model for p53 in maintaining genomic integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The molecular biology of lung cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Mutant p53 protein as a biomarker of chemical carcinogenesis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Acrylonitrile exposure: the effect on p53 and p21(WAF1) protein levels in the blood plasma of occupationally exposed workers and in vitro in human diploid lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

A critical evaluation of DNA adducts as biological markers for human exposure to polycyclic aromatic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The effect of dibenzo[a,1]pyrene and benzo[a]pyrene on human diploid lung fibroblasts: the induction of DNA adducts, expression of p53 and p21(WAF1) proteins and cell cycle distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

A study of multiple biomarkers in coke oven workers--a cross-sectional study in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Lung cancer pathogenesis associated with wood smoke exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

p53 protein is absent from the serum of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Prognostic factors in NSCLC. Recent experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The relationship between serum p53 autoantibodies and characteristics of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

p53 autoantibodies predict subsequent development of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Differences in tumor-associated protein levels among middle-age Flemish women in association with area of residence and exposure to pollutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum p53 antibodies: predictors of survival in small-cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Biomarkers in non-small cell lung cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum ras (p21) as a marker for occupationally derived lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Quantification of free circulating DNA as a diagnostic marker in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Early Detection of Lung Cancer Using Serum RNA or DNA Markers: Ready for “Prime Time” or for Validation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Serum Anti-p53 Antibodies and Prognosis of Patients With Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.555

21 January 2018

Identifiers

DOI

10.1586/14737159.7.5.555

1 reference

17 August 2017

1 reference